ResearcherHerlev HospitalActive in the last 2 years

Rikke Løvendahl Eefsen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1421-1792; OpenAlex author ID A5065983624. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2025.116095 ↗
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pan… Co-author DOI 10.1158/1078-0432.ccr-24-0645 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Per Pfeiffer · 2 shared papers, 2024–2025 · strength 0.43
- Paper Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor surv… DOI 10.1016/j.ejca.2025.116095 ↗
- Paper Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel … DOI 10.1158/1078-0432.ccr-24-0645 ↗
I.M. Chen · 1 shared paper, 2025 · strength 0.26
- Paper Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor surv… DOI 10.1016/j.ejca.2025.116095 ↗
Dan Calatayud · 1 shared paper, 2025 · strength 0.26
- Paper Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor surv… DOI 10.1016/j.ejca.2025.116095 ↗
Astrid Zedlitz Johansen · 1 shared paper, 2025 · strength 0.26
- Paper Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor surv… DOI 10.1016/j.ejca.2025.116095 ↗
Gunilla Høyer‐Hansen · 1 shared paper, 2025 · strength 0.26
- Paper Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor surv… DOI 10.1016/j.ejca.2025.116095 ↗
Ahmad Hussein Awada · 1 shared paper, 2024 · strength 0.17
- Paper Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel … DOI 10.1158/1078-0432.ccr-24-0645 ↗
Dirk Arnold · 1 shared paper, 2024 · strength 0.17
- Paper Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel … DOI 10.1158/1078-0432.ccr-24-0645 ↗
Eric Van Cutsem · 1 shared paper, 2024 · strength 0.17
- Paper Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel … DOI 10.1158/1078-0432.ccr-24-0645 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.